Spinal column chordoma: Prognostic significance of clinical variables and T (brachyury) gene SNP rs2305089 for local recurrence and overall survival

Chetan Bettegowda, Stephen Yip, Sheng-fu Lo, Charles G. Fisher, Stefano Boriani, Laurence D. Rhines, Joanna Y. Wang, Aron Lazary, Marco Gambarotti, Wei Lien Wang, Alessandro Luzzati, Mark B. Dekutoski, Mark H. Bilsky, Dean Chou, Michael G. Fehlings, Edward F McCarthy, Nasir A. Quraishi, Jeremy J. Reynolds, Daniel Sciubba, Richard P. WilliamsJean Paul Wolinsky, Patricia L. Zadnik, Ming Zhang, Niccole M. Germscheid, Vasiliki Kalampoki, Peter Pal Varga, Ziya L. Gokaslan

Research output: Contribution to journalArticle

Abstract

Background: Chordomas are rare, locally aggressive bony tumors associated with poor outcomes. Recently, the single nucleotide polymorphism (SNP) rs2305089 in the T (brachyury) gene was strongly associated with sporadic chordoma development, but its clinical utility is undetermined. Methods: In 333 patients with spinal chordomas, we identified prognostic factors for local recurrence-free survival (LRFS) and overall survival and assessed the prognostic significance of the rs2305089 SNP. Results: The median LRFS was 5.2 years from the time of surgery (95% CI: 3.8-6.0); greater tumor volume (≥100cm3) (hazard ratio [HR] = 1.99, 95% CI: 1.26-3.15, P =.003) and Enneking inappropriate resections (HR = 2.35, 95% CI: 1.37-4.03, P =.002) were independent predictors of LRFS. The median overall survival was 7.0 years (95% CI: 5.8-8.4), and was associated with older age at surgery (HR = 1.11 per 5-year increase, 95% CI: 1.02-1.21, P =.012) and previous surgical resection (HR = 1.73, 95% CI: 1.03-2.89, P =.038). One hundred two of 109 patients (93.6%) with available pathologic specimens harbored the A variant at rs2305089; these patients had significantly improved survival compared with those lacking the variant (P = .001), but there was no association between SNP status and LRFS (P = .876). Conclusions: The ability to achieve a wide en bloc resection at the time of the primary surgery is a critical preoperative consideration, as subtotal resections likely complicate later management. This is the first time the rs2305089 SNP has been implicated in the prognosis of individuals with chordoma, suggesting that screening all patients may be instructive for risk stratification.

Original languageEnglish (US)
Pages (from-to)405-413
Number of pages9
JournalNeuro-Oncology
Volume19
Issue number3
DOIs
StatePublished - Mar 1 2017

Fingerprint

Chordoma
Single Nucleotide Polymorphism
Spine
Recurrence
Survival
Genes
Brachyury protein
Tumor Burden

Keywords

  • Brachyury
  • Chordoma
  • Rs2305089
  • SNP
  • Spine
  • T gene

ASJC Scopus subject areas

  • Oncology
  • Clinical Neurology
  • Cancer Research

Cite this

Spinal column chordoma : Prognostic significance of clinical variables and T (brachyury) gene SNP rs2305089 for local recurrence and overall survival. / Bettegowda, Chetan; Yip, Stephen; Lo, Sheng-fu; Fisher, Charles G.; Boriani, Stefano; Rhines, Laurence D.; Wang, Joanna Y.; Lazary, Aron; Gambarotti, Marco; Wang, Wei Lien; Luzzati, Alessandro; Dekutoski, Mark B.; Bilsky, Mark H.; Chou, Dean; Fehlings, Michael G.; McCarthy, Edward F; Quraishi, Nasir A.; Reynolds, Jeremy J.; Sciubba, Daniel; Williams, Richard P.; Wolinsky, Jean Paul; Zadnik, Patricia L.; Zhang, Ming; Germscheid, Niccole M.; Kalampoki, Vasiliki; Varga, Peter Pal; Gokaslan, Ziya L.

In: Neuro-Oncology, Vol. 19, No. 3, 01.03.2017, p. 405-413.

Research output: Contribution to journalArticle

Bettegowda, C, Yip, S, Lo, S, Fisher, CG, Boriani, S, Rhines, LD, Wang, JY, Lazary, A, Gambarotti, M, Wang, WL, Luzzati, A, Dekutoski, MB, Bilsky, MH, Chou, D, Fehlings, MG, McCarthy, EF, Quraishi, NA, Reynolds, JJ, Sciubba, D, Williams, RP, Wolinsky, JP, Zadnik, PL, Zhang, M, Germscheid, NM, Kalampoki, V, Varga, PP & Gokaslan, ZL 2017, 'Spinal column chordoma: Prognostic significance of clinical variables and T (brachyury) gene SNP rs2305089 for local recurrence and overall survival', Neuro-Oncology, vol. 19, no. 3, pp. 405-413. https://doi.org/10.1093/neuonc/now156
Bettegowda, Chetan ; Yip, Stephen ; Lo, Sheng-fu ; Fisher, Charles G. ; Boriani, Stefano ; Rhines, Laurence D. ; Wang, Joanna Y. ; Lazary, Aron ; Gambarotti, Marco ; Wang, Wei Lien ; Luzzati, Alessandro ; Dekutoski, Mark B. ; Bilsky, Mark H. ; Chou, Dean ; Fehlings, Michael G. ; McCarthy, Edward F ; Quraishi, Nasir A. ; Reynolds, Jeremy J. ; Sciubba, Daniel ; Williams, Richard P. ; Wolinsky, Jean Paul ; Zadnik, Patricia L. ; Zhang, Ming ; Germscheid, Niccole M. ; Kalampoki, Vasiliki ; Varga, Peter Pal ; Gokaslan, Ziya L. / Spinal column chordoma : Prognostic significance of clinical variables and T (brachyury) gene SNP rs2305089 for local recurrence and overall survival. In: Neuro-Oncology. 2017 ; Vol. 19, No. 3. pp. 405-413.
@article{873cc2d3442c4043af64172907be9940,
title = "Spinal column chordoma: Prognostic significance of clinical variables and T (brachyury) gene SNP rs2305089 for local recurrence and overall survival",
abstract = "Background: Chordomas are rare, locally aggressive bony tumors associated with poor outcomes. Recently, the single nucleotide polymorphism (SNP) rs2305089 in the T (brachyury) gene was strongly associated with sporadic chordoma development, but its clinical utility is undetermined. Methods: In 333 patients with spinal chordomas, we identified prognostic factors for local recurrence-free survival (LRFS) and overall survival and assessed the prognostic significance of the rs2305089 SNP. Results: The median LRFS was 5.2 years from the time of surgery (95{\%} CI: 3.8-6.0); greater tumor volume (≥100cm3) (hazard ratio [HR] = 1.99, 95{\%} CI: 1.26-3.15, P =.003) and Enneking inappropriate resections (HR = 2.35, 95{\%} CI: 1.37-4.03, P =.002) were independent predictors of LRFS. The median overall survival was 7.0 years (95{\%} CI: 5.8-8.4), and was associated with older age at surgery (HR = 1.11 per 5-year increase, 95{\%} CI: 1.02-1.21, P =.012) and previous surgical resection (HR = 1.73, 95{\%} CI: 1.03-2.89, P =.038). One hundred two of 109 patients (93.6{\%}) with available pathologic specimens harbored the A variant at rs2305089; these patients had significantly improved survival compared with those lacking the variant (P = .001), but there was no association between SNP status and LRFS (P = .876). Conclusions: The ability to achieve a wide en bloc resection at the time of the primary surgery is a critical preoperative consideration, as subtotal resections likely complicate later management. This is the first time the rs2305089 SNP has been implicated in the prognosis of individuals with chordoma, suggesting that screening all patients may be instructive for risk stratification.",
keywords = "Brachyury, Chordoma, Rs2305089, SNP, Spine, T gene",
author = "Chetan Bettegowda and Stephen Yip and Sheng-fu Lo and Fisher, {Charles G.} and Stefano Boriani and Rhines, {Laurence D.} and Wang, {Joanna Y.} and Aron Lazary and Marco Gambarotti and Wang, {Wei Lien} and Alessandro Luzzati and Dekutoski, {Mark B.} and Bilsky, {Mark H.} and Dean Chou and Fehlings, {Michael G.} and McCarthy, {Edward F} and Quraishi, {Nasir A.} and Reynolds, {Jeremy J.} and Daniel Sciubba and Williams, {Richard P.} and Wolinsky, {Jean Paul} and Zadnik, {Patricia L.} and Ming Zhang and Germscheid, {Niccole M.} and Vasiliki Kalampoki and Varga, {Peter Pal} and Gokaslan, {Ziya L.}",
year = "2017",
month = "3",
day = "1",
doi = "10.1093/neuonc/now156",
language = "English (US)",
volume = "19",
pages = "405--413",
journal = "Neuro-Oncology",
issn = "1522-8517",
publisher = "Oxford University Press",
number = "3",

}

TY - JOUR

T1 - Spinal column chordoma

T2 - Prognostic significance of clinical variables and T (brachyury) gene SNP rs2305089 for local recurrence and overall survival

AU - Bettegowda, Chetan

AU - Yip, Stephen

AU - Lo, Sheng-fu

AU - Fisher, Charles G.

AU - Boriani, Stefano

AU - Rhines, Laurence D.

AU - Wang, Joanna Y.

AU - Lazary, Aron

AU - Gambarotti, Marco

AU - Wang, Wei Lien

AU - Luzzati, Alessandro

AU - Dekutoski, Mark B.

AU - Bilsky, Mark H.

AU - Chou, Dean

AU - Fehlings, Michael G.

AU - McCarthy, Edward F

AU - Quraishi, Nasir A.

AU - Reynolds, Jeremy J.

AU - Sciubba, Daniel

AU - Williams, Richard P.

AU - Wolinsky, Jean Paul

AU - Zadnik, Patricia L.

AU - Zhang, Ming

AU - Germscheid, Niccole M.

AU - Kalampoki, Vasiliki

AU - Varga, Peter Pal

AU - Gokaslan, Ziya L.

PY - 2017/3/1

Y1 - 2017/3/1

N2 - Background: Chordomas are rare, locally aggressive bony tumors associated with poor outcomes. Recently, the single nucleotide polymorphism (SNP) rs2305089 in the T (brachyury) gene was strongly associated with sporadic chordoma development, but its clinical utility is undetermined. Methods: In 333 patients with spinal chordomas, we identified prognostic factors for local recurrence-free survival (LRFS) and overall survival and assessed the prognostic significance of the rs2305089 SNP. Results: The median LRFS was 5.2 years from the time of surgery (95% CI: 3.8-6.0); greater tumor volume (≥100cm3) (hazard ratio [HR] = 1.99, 95% CI: 1.26-3.15, P =.003) and Enneking inappropriate resections (HR = 2.35, 95% CI: 1.37-4.03, P =.002) were independent predictors of LRFS. The median overall survival was 7.0 years (95% CI: 5.8-8.4), and was associated with older age at surgery (HR = 1.11 per 5-year increase, 95% CI: 1.02-1.21, P =.012) and previous surgical resection (HR = 1.73, 95% CI: 1.03-2.89, P =.038). One hundred two of 109 patients (93.6%) with available pathologic specimens harbored the A variant at rs2305089; these patients had significantly improved survival compared with those lacking the variant (P = .001), but there was no association between SNP status and LRFS (P = .876). Conclusions: The ability to achieve a wide en bloc resection at the time of the primary surgery is a critical preoperative consideration, as subtotal resections likely complicate later management. This is the first time the rs2305089 SNP has been implicated in the prognosis of individuals with chordoma, suggesting that screening all patients may be instructive for risk stratification.

AB - Background: Chordomas are rare, locally aggressive bony tumors associated with poor outcomes. Recently, the single nucleotide polymorphism (SNP) rs2305089 in the T (brachyury) gene was strongly associated with sporadic chordoma development, but its clinical utility is undetermined. Methods: In 333 patients with spinal chordomas, we identified prognostic factors for local recurrence-free survival (LRFS) and overall survival and assessed the prognostic significance of the rs2305089 SNP. Results: The median LRFS was 5.2 years from the time of surgery (95% CI: 3.8-6.0); greater tumor volume (≥100cm3) (hazard ratio [HR] = 1.99, 95% CI: 1.26-3.15, P =.003) and Enneking inappropriate resections (HR = 2.35, 95% CI: 1.37-4.03, P =.002) were independent predictors of LRFS. The median overall survival was 7.0 years (95% CI: 5.8-8.4), and was associated with older age at surgery (HR = 1.11 per 5-year increase, 95% CI: 1.02-1.21, P =.012) and previous surgical resection (HR = 1.73, 95% CI: 1.03-2.89, P =.038). One hundred two of 109 patients (93.6%) with available pathologic specimens harbored the A variant at rs2305089; these patients had significantly improved survival compared with those lacking the variant (P = .001), but there was no association between SNP status and LRFS (P = .876). Conclusions: The ability to achieve a wide en bloc resection at the time of the primary surgery is a critical preoperative consideration, as subtotal resections likely complicate later management. This is the first time the rs2305089 SNP has been implicated in the prognosis of individuals with chordoma, suggesting that screening all patients may be instructive for risk stratification.

KW - Brachyury

KW - Chordoma

KW - Rs2305089

KW - SNP

KW - Spine

KW - T gene

UR - http://www.scopus.com/inward/record.url?scp=85018304654&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018304654&partnerID=8YFLogxK

U2 - 10.1093/neuonc/now156

DO - 10.1093/neuonc/now156

M3 - Article

C2 - 27663388

AN - SCOPUS:85018304654

VL - 19

SP - 405

EP - 413

JO - Neuro-Oncology

JF - Neuro-Oncology

SN - 1522-8517

IS - 3

ER -